The U.S. Food and Drug Administration approved imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio) on September 18, 2026, for adults with estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease progressed following at least one line of endocrine therapy. Both agents are manufactured by Eli Lilly and Company. Concurrently, the FDA approved the Guardant360 CDx assay as a companion diagnostic to identify patients with ESR1 mutations eligible for this regimen.
Approval of the combination was supported by progression-free survival data from the EMBER-3 trial, though the benefit was observed specifically in patients with ESR1-mutated tumors. Notably, imlunestrant monotherapy did not demonstrate a PFS improvement over investigator’s choice of endocrine therapy in either the overall or ESR1 mutation-not-detected populations, meaning the clinical benefit of the approval is confined to the ESR1-mutated subgroup.
Key finding
In an exploratory subgroup of 159 patients with ESR1-mutated tumors, imlunestrant plus abemaciclib reduced the risk of progression or death by 47% compared with imlunestrant alone (HR 0.53; 95% CI: 0.35, 0.80), nearly doubling median PFS from 5.5 to 11.1 months. Overall survival data remain immature and the monotherapy arm did not outperform standard endocrine therapy in non-ESR1-mutated patients.
Study Design
| Trial | EMBER-3 (NCT04975308); randomized, open-label, active-controlled, multicenter |
|---|---|
| Population | 874 adults with ER-positive, HER2-negative locally advanced or metastatic breast cancer previously treated with an aromatase inhibitor, alone or with a CDK4/6 inhibitor; patients eligible for a PARP inhibitor were excluded |
| Treatment | 1:1:1 randomization to imlunestrant monotherapy, investigator’s choice of endocrine therapy (fulvestrant or exemestane), or imlunestrant plus abemaciclib |
| Primary endpoint | Investigator-assessed progression-free survival (PFS) per RECIST v1.1 in the overall population, comparing imlunestrant plus abemaciclib to imlunestrant monotherapy |
| Key secondary endpoints | Overall survival (OS); investigator-assessed objective response rate (ORR) |
ESR1 mutational status was assessed centrally using the Guardant360 CDx assay from blood circulating tumor DNA, with eligibility restricted to specific ESR1 mutations in the ligand-binding domain. Randomization was stratified by prior CDK4/6 inhibitor use, presence of visceral metastasis, and geographic region.
Results and Safety
The PFS comparison of imlunestrant plus abemaciclib versus imlunestrant monotherapy in the overall trial population was statistically significant; however, the FDA’s approval rationale centers on the ESR1-mutated subgroup, given that monotherapy did not show benefit over standard endocrine therapy outside that population. In the exploratory analysis of 159 ESR1-mutated patients, median PFS was 11.1 months (95% CI: 7.4, 13.7) in the combination arm versus 5.5 months (95% CI: 3.8, 7.2) in the imlunestrant-alone arm, corresponding to a hazard ratio of 0.53 (95% CI: 0.35, 0.80). Objective response rates in this subgroup were 35% (95% CI: 22, 48) for the combination and 15% (95% CI: 7, 23) for monotherapy. Overall survival data were immature at the time of interim analysis, with 35% of events observed in the ESR1-mutated population.
The prescribing information for imlunestrant carries a warning for embryo-fetal toxicity. Abemaciclib’s prescribing information includes warnings and precautions for diarrhea, neutropenia, interstitial lung disease or pneumonitis, hepatotoxicity, venous thromboembolism, and embryo-fetal toxicity. The recommended dosage of imlunestrant is 400 mg orally once daily on an empty stomach (at least two hours before food or one hour after food); abemaciclib is dosed at 150 mg orally twice daily with or without food, both continued until disease progression or unacceptable toxicity.
Clinical Context
ESR1 mutations are a recognized mechanism of acquired resistance to aromatase inhibitor-based endocrine therapy and are detectable in a meaningful proportion of patients with ER-positive, HER2-negative metastatic breast cancer who progress on first-line treatment. The approval of imlunestrant plus abemaciclib offers a CDK4/6 inhibitor-based combination option specifically targeting this resistance mechanism, with companion diagnostic-guided patient selection via the Guardant360 CDx liquid biopsy assay. The indication fills a gap for patients who have already received an aromatase inhibitor, with or without a CDK4/6 inhibitor, and harbor an ESR1 mutation at progression.
Overall survival data were immature at the interim analysis, leaving the magnitude of long-term benefit undefined. The approval rests on an exploratory subgroup analysis rather than a pre-specified primary endpoint in the ESR1-mutated population, and the clinical positioning of this regimen relative to other approved options in the ESR1-mutated setting, including other selective estrogen receptor degraders, will require further comparative evidence.
Sources
- U.S. Food and Drug Administration. “FDA Approves Imlunestrant in Combination with Abemaciclib for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer.” Drug approval announcement. September 18, 2026. View source.
AI disclosure: This article was prepared with assistance from generative AI using the source material cited above. It was reviewed and edited by Brandon Twyford before publication.
